# Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes

> **NCT01865318** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 36 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** insulin degludec

## Key facts

- **NCT ID:** NCT01865318
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01865318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01865318, "Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01865318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*